EGFR and metastatic neoplasm: Predominant oncogenic alternative TrkAIII splicing, originally identified and associated with advanced-stage metastatic disease and post-therapeutic relapse in human neuroblastomas (NBs), has also been detected in a subset of EGFR and EGFRvIII negative stage IV glioblastomas and in metastatic melanoma.